EU MDR Readiness Reviews — Structured, Independent, Fixed-Scope
B Plus Solutions delivers independent regulatory document reviews for EU MDR compliance.
Structured feedback. Clear risk flags. Submission-ready insight.
Our Services
Regulatory and Strategic Support
EU MDR regulatory strategy, gap assessments, mock audits, and technical documentation review to support manufacturers in preparing compliant and submission-ready documentation.
Clinical and Post-Market Documentation
Clinical Evaluation (CEP, CER, SSCP), PMS and PMCF documentation, literature reviews, and post-market regulatory documentation aligned with EU MDR requirements.
About B+ Solutions
B+ Solutions provides independent regulatory and clinical documentation support for medical device manufacturers navigating EU MDR requirements. With experience on both the manufacturer side and the notified body side, B+ Solutions understands how technical documentation is developed, reviewed, and assessed during conformity assessment. This perspective allows us to deliver structured, practical feedback that strengthens regulatory submissions and helps teams move forward with confidence.
● LIVE
Industry & Compliance Updates
"medical device" - Google News Google News
- Qatar Plastic Catheter Market 2026 Analysis and Forecast to 2035 - IndexBoxon 18 April 2026 at 01:10
Qatar Plastic Catheter Market 2026 Analysis and Forecast to 2035 IndexBox
- Home Infusion Therapy Devices Market Forecast Points Higher Toward 2035, Driven by Aging Demographics - IndexBoxon 17 April 2026 at 22:01
Home Infusion Therapy Devices Market Forecast Points Higher Toward 2035, Driven by Aging Demographics IndexBox
- Northern America Drainable Two-Piece Colostomy Drainage Bags Market 2026 Analysis and Forecast to 2035 - IndexBoxon 17 April 2026 at 21:16
Northern America Drainable Two-Piece Colostomy Drainage Bags Market 2026 Analysis and Forecast to 2035 IndexBox
- Autoimmune, Inflammatory-Focused Biotech Odyssey Files for IPO - Bloomberg.comon 17 April 2026 at 20:52
Autoimmune, Inflammatory-Focused Biotech Odyssey Files for IPO Bloomberg.com
- This Week at FDA: Antibiotic impurities guidance, new nitrosamine woes, and FDA’s busy calendar - RAPS.orgon 17 April 2026 at 20:47
This Week at FDA: Antibiotic impurities guidance, new nitrosamine woes, and FDA’s busy calendar RAPS.org